Is The Market Rewarding Highway Holdings Limited (NASDAQ:HIHO) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

HIGHWAY HOLDINGS LTD (HIHO) furnished an SEC Form 6-K — earnings release. Attached to this Report on Form 6-K is the press release issued by the registrant on July 20, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto d

Highway Holdings Ltd (Nasdaq: HIHO) said it signed a non-binding LOI with Guangdong Huahu New Energy Technology (Wowtiger) to form a Hong Kong joint venture. Highway would contribute about $2.0m cash for 57% ownership, Huahu about $1.5m in products/technology for 43%. The venture would pursue SKD rights in Germany, Italy, the US and some South American markets, with milestone-based restricted-share issuances up to 400,000 shares plus other incentives.

Highway Holdings (NASDAQ:HIHO) reported Q1 FY2027 EPS of $0.02 versus $0.01 a year earlier, revenue of $1.999M versus $1.547M, and operating income improving from a $138K loss to a $59K profit. Cash and cash equivalents were $3.9M. CEO Roland Kohl cited the loss of a long-standing Myanmar customer and said the firm is shifting toward partnerships and a more product-driven model.

Highway Holdings (Nasdaq: HIHO) reported fiscal Q4 net sales of $0.93 million vs $1.5 million a year earlier, with gross profit of $246,000 and a net loss of $1.1 million ($0.24/share). Full-year net sales fell to $4.8 million from $7.4 million, with a $1.5 million net loss. The company cited reduced orders tied to Myanmar instability and tariffs, plus a $125,000 impairment charge, and said its Regent-Feinbau acquisition aims to diversify OEM exposure.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.